Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:EPRX NASDAQ:IPSC NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.19-2.6%$4.29$1.21▼$3.81$103.48M0.68261,100 shs692,497 shsEPRXEupraxia Pharmaceuticals$6.52-2.5%$6.78$4.88▼$9.32$423.92M1.05255,997 shs277,218 shsIPSCCentury Therapeutics$2.40-1.2%$2.28$0.44▼$3.04$432.84M1.551.57 million shs1.03 million shsPRTCPureTech Health$17.42$17.40$14.50▼$19.92$424.04M1.1518,480 shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.72%-4.77%+19.37%+110.55%EPRXEupraxia Pharmaceuticals0.00%+1.53%+12.44%-5.77%+22.42%IPSCCentury Therapeutics0.00%+4.74%+14.08%+10.96%+333.93%PRTCPureTech Health0.00%0.00%0.00%+11.77%-3.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.19-2.6%$4.29$1.21▼$3.81$103.48M0.68261,100 shs692,497 shsEPRXEupraxia Pharmaceuticals$6.52-2.5%$6.78$4.88▼$9.32$423.92M1.05255,997 shs277,218 shsIPSCCentury Therapeutics$2.40-1.2%$2.28$0.44▼$3.04$432.84M1.551.57 million shs1.03 million shsPRTCPureTech Health$17.42$17.40$14.50▼$19.92$424.04M1.1518,480 shsN/A7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+0.72%-4.77%+19.37%+110.55%EPRXEupraxia Pharmaceuticals0.00%+1.53%+12.44%-5.77%+22.42%IPSCCentury Therapeutics0.00%+4.74%+14.08%+10.96%+333.93%PRTCPureTech Health0.00%0.00%0.00%+11.77%-3.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AEPRXEupraxia Pharmaceuticals 2.89Moderate Buy$18.00176.07% UpsideIPSCCentury Therapeutics 2.43Hold$4.7597.92% UpsidePRTCPureTech Health 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AADI, IPSC, EPRX, and PRTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/25/2026EPRXEupraxia Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$17.005/27/2026IPSCCentury Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.005/21/2026EPRXEupraxia Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.005/18/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/7/2026EPRXEupraxia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/4/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/22/2026EPRXEupraxia Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.004/21/2026EPRXEupraxia Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026IPSCCentury Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $5.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M4.13N/AN/A$4.29 per share0.98EPRXEupraxia PharmaceuticalsN/AN/AN/AN/A$1.41 per shareN/AIPSCCentury Therapeutics$109.16M3.97$0.01 per share182.71$1.82 per share1.32PRTCPureTech Health$4.66M91.01N/AN/A$12.65 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AEPRXEupraxia Pharmaceuticals-$38.58M-$1.05N/AN/AN/AN/A-87.56%-51.20%8/11/2026 (Estimated)IPSCCentury Therapeutics-$9.58M-$1.14N/AN/AN/AN/A-49.89%-37.42%8/13/2026 (Estimated)PRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/A8/27/2026 (Estimated)Latest AADI, IPSC, EPRX, and PRTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026IPSCCentury Therapeutics-$0.15-$0.11+$0.04-$0.11$2.87 millionN/A5/12/2026Q1 2026EPRXEupraxia Pharmaceuticals-$0.22-$0.23-$0.01-$0.23N/AN/A4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54EPRXEupraxia Pharmaceuticals0.0219.3119.31IPSCCentury TherapeuticsN/A10.2510.25PRTCPureTech HealthN/A6.596.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%EPRXEupraxia PharmaceuticalsN/AIPSCCentury Therapeutics50.20%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%EPRXEupraxia PharmaceuticalsN/AIPSCCentury Therapeutics2.40%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataEPRXEupraxia Pharmaceuticals2965.02 millionN/AN/AIPSCCentury Therapeutics170180.35 million176.03 millionOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionableAADI, IPSC, EPRX, and PRTC HeadlinesRecent News About These CompaniesPureTech entity Celea raises $180 million to move lung disease drug into late stage trialJuly 2, 2026 | reuters.comPureTech Health plc American Depositary Shares (PRTC) Real-TimeJuly 1, 2026 | nasdaq.com2 UK shares tipped to more than double my money in 2026!June 20, 2026 | uk.finance.yahoo.comPureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy VolunteersJune 9, 2026 | finance.yahoo.comPureTech to Showcase Deupirfenidone Program at the American Thoracic Society International ConferenceMay 13, 2026 | businesswire.comPureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPOMay 1, 2026 | proactiveinvestors.co.ukPureTech Announces Annual Results for Year Ended December 31, 2025April 29, 2026 | businesswire.comPureTech Health: Notice of ResultsApril 13, 2026 | businesswire.comPureTech Gains on ResultsApril 2, 2026 | baystreet.caPureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care MedicineApril 2, 2026 | businesswire.comPureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansMarch 25, 2026 | businesswire.comPureTech to Present at the Leerink Partners Global Healthcare ConferenceFebruary 25, 2026 | businesswire.comPureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisFebruary 19, 2026 | businesswire.comPureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comPureTech to Present at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2026 | finance.yahoo.comPureTech CEO to present at JP Morgan Healthcare ConferenceJanuary 6, 2026 | msn.comPureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the companyJanuary 3, 2026 | finance.yahoo.comPureTech Appoints Robert Lyne as Chief Executive OfficerDecember 18, 2025 | businesswire.comPeel Hunt Limited reiterates PureTech Health plc - Depositary Receipt (PRTC) buy recommendationDecember 16, 2025 | msn.comPureTech stock falls after FDA meeting on IPF drugDecember 8, 2025 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAADI, IPSC, EPRX, and PRTC Company DescriptionsAadi Bioscience NASDAQ:AADI$4.19 -0.11 (-2.56%) As of 07/2/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Eupraxia Pharmaceuticals NASDAQ:EPRX$6.52 -0.17 (-2.54%) Closing price 04:00 PM EasternExtended Trading$6.52 0.00 (-0.08%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Century Therapeutics NASDAQ:IPSC$2.40 -0.03 (-1.23%) Closing price 04:00 PM EasternExtended Trading$2.40 0.00 (-0.21%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.PureTech Health NASDAQ:PRTC$17.42 0.00 (0.00%) As of 07/2/2026PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
